Erbelding EJ, Post D, Stemmy E, Roberts PC, et al. A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases. J Infect Dis 2018 Feb 28
A priority for the National Institute of Allergy and Infectious Diseases (NIAID) is development of an influenza vaccine providing durable protection against multiple influenza strains, including those that may cause a pandemic, i.e., a universal influenza vaccine. To invigorate research efforts, NIAID developed a strategic plan focused on knowledge gaps in three major research areas, as well as additional resources required to ensure progress towards a universal influenza vaccine. NIAID will use this plan as a foundation for future investments in influenza research and will support and coordinate a consortium of multidisciplinary scientists focused on accelerating progress towards this goal.
See Also:
Latest articles in those days:
- Phylogenetic Analysis of Highly Pathogenic Avian Influenza H7 Viruses in Australia and New Zealand Suggests Local Viral Evolution 18 hours ago
- AI-Powered Identification of Human Cell Surface Protein Interactors of the Hemagglutinin Glycoprotein of High-Pandemic-Risk H5N1 Influenza Virus 18 hours ago
- Seasonal Influenza Vaccination Uptake and Intentions Among Nursing Students in Hong Kong 18 hours ago
- Intranasal Mosaic H1N1 Live Attenuated Influenza Vaccine Elicits Broad Cross-Reactive Immunity and Protection Against Group 1 and 2 Influenza A Viruses 18 hours ago
- Changing Landscape of Pediatric Influenza in Northern Mexico: A Comparative Clinical and Virological Study 18 hours ago
[Go Top] [Close Window]


